Bromocriptine mesylate: Food and Drug Administration approved new approach in therapy of non-insulin dependant diabetes mellitus with poor glycemic control
Food and Drug Administration (FDA) approved bromocriptine mesylate, a quick release formulation, 0.8 mg tablets, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Bromocriptine products were previously approved by the FDA for the treatment of pit...
Shranjeno v:
| Glavni avtor: | |
|---|---|
| Format: | Knjiga |
| Izdano: |
Wolters Kluwer Medknow Publications,
2010-01-01T00:00:00Z.
|
| Teme: | |
| Online dostop: | Connect to this object online. |
| Oznake: |
Označite
Brez oznak, prvi označite!
|
Internet
Connect to this object online.3rd Floor Main Library
| Signatura: |
A1234.567 |
|---|---|
| Kopija 1 | Prosto |